Evidence Favoring the Use of an α2-Selective Vasopressor Agent for Cardiopulmonary Resuscitation

Circulation

Volumn 108, Issue 21, 2003, Pages 2716-2721

  Pellis, Tommaso ^a   Weil, Max Harry ^a,b   Tang, Wanchun ^a,b   Sun, Shijie ^a,b   Xie, Jing ^a   Song, Lei ^a   Checchia, Paul ^c  

^a INSTITUTE OF CRITICAL CARE MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiopulmonary resuscitation; Epinephrine; Receptors, adrenergic, alpha; Receptors, adrenergic, beta; Vasopressin

Indexed keywords

ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; PRAZOSIN; PROPRANOLOL; TROPONIN I; VASOPRESSIN; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; COMPRESSION THERAPY; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFECT; DRUG PREFERENCE; HEART OUTPUT; HEART VENTRICLE FIBRILLATION; HYPOTHESIS; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RESUSCITATION; STATISTICAL SIGNIFICANCE; ANIMAL; BLOOD PRESSURE; CARDIOVERSION; CONVALESCENCE; DISEASE MODEL; DRUG COMBINATION; HEART ARREST; HEART MASSAGE; METHODOLOGY; SWINE; TREATMENT OUTCOME;

ADRENERGIC AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CARDIOPULMONARY RESUSCITATION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ELECTRIC COUNTERSHOCK; EPINEPHRINE; HEART ARREST; HEART MASSAGE; MALE; PRAZOSIN; PROPRANOLOL; RECOVERY OF FUNCTION; RESPIRATION, ARTIFICIAL; SWINE; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS; VASOPRESSINS; VENTRICULAR FIBRILLATION;

EID: 0345707536     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000096489.40209.DD     Document Type: Article

References (36)

1. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2000;8(suppl):I-129-I-135,
2. The European Resuscitation Council. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Resuscitation. 2000;46:155-162.
3. Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA. 1999;281:1182-1188.
4. Brain Resuscitation Council Trial II Study Group. A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. N Engl J Med. 1991;324:1225-1231.
5. Brown CG, Martin DR, Pepe P. A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. N Engl J Med. 1992;327:1051-1055.
6. Stiell IG, Herbert PC, Weitzman BN. High-dose epinephrine in adult cardiac arrest. N Engl J Med. 1992;327:1045-1050.
7. Tang W, Weil MH, Sun S, et al. Epinephrine increases the severity of post-resuscitation myocardial dysfunction. Circulation. 1995;92:3089-3093.
8. Xie J, Weil MH, Sun SJ, et al. High-energy defibrillation increases the severity of postresuscitation myocardial dysfunction. Circulation. 1997;96:683-688.
9. Tang W, Weil MH, Sun SJ, et al. The effects of conventional monophasic defibrillation on postresuscitation myocardial function. J Am Coll Cardiol. 1999;4:815-822.
10. Kern KB, Hilwig RW, Rhee KH, et al. Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning. J Am Coll Cardiol. 1996;28:232-240.
11. Lindner KH, Strohmenger HU, Ensinger H, et al. Stress hormone during and after cardiopulmonary resuscitation. Anesthesiology. 1992;77:662-668.
12. Lindner KH, Brinkmann A, Pfenninger EG, et al. Effect of vasopressin on hemodynamic variables, organ blood flow and acid base status in a pig model of cardiopulmonary resuscitation. Anesth Analg. 1993;77:427-345.
13. Lindner KH, Dirks B, Strohmenger HU, et al. A randomized comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet. 1997;349:535-537.
14. Niemann JT, Haynes KS, Gardner D, et al. Post-countershock pulseless rhythms: response to CPR, artificial cardiac pacing, and adrenergic agonists. Ann Emerg Med. 1986;15:112-120.
15. Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw Hill; 1996:729.
16. Garcia-Villalon AI, Garcia JL, Fernandez N, et al. Regional differences in the arterial response to vasopressin: role of endothelial nitric oxide. Br J Pharmacol. 1996;118:1848-1854.
17. Graf BM, Fisher B, Martin E, et al. Differential effects of arginine vasopressin on isolated guinea pig heart function during perfusion at constant flow and constant pressure. J Cardiovasc Pharmacol. 1997;29:1-7.
18. Endoh M, Takanashi M, Norota I. Effects of vasopressin on phosphoinositide hydrolysis and myocardial contractility. Eur J Pharmacol. 1992;218:355-358.
19. Nozari A, Rubertsson S, Wiklund L. Differences in the pharmacodynamics of epinephrine and vasopressin during and after experimental cardiopulmonary resuscitation. Resuscitation. 2001;49:59-72.
20. Redding JS, Pearson JW. Evaluation of drugs for cardiac resuscitation. Anesthesiology. 1963;24:203-207.
21. Ditchey RV, Lindenfeld JA. Failure of epinephrine to improve the balance between oxygen supply and demand during closed-chest resuscitation in dogs. Circulation. 1988;78:382-389.
22. Adams JE III, Bodor GS, Davila-Roman VG, et al. Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation. 1993;88:101-106.
23. Checchia P, Borensztajn J, Shulman ST. Circulating cardiac troponin I levels in Kawasaki disease. Pediatr Cardiol. 2001;22:102-106.
24. Walker MJ, Curtis MJ, Hearse DJ, et al. The Lamberth Convention: guidelines for the study of arrhythmias in ischemia, infarction and reperfusion. Cardiovasc Res. 1988;22:447-455.
25. Kern KB, Ewy GA, Voorhees WD, et al. Myocardial perfusion pressure: a predictor of 24-h survival during prolonged cardiac arrest in dogs. Resuscitation. 1988;16:241-250.
26. Ditchey RV, Rubio-Perez A, Slinker BK. Beta-adrenergic blockade reduces myocardial injury during experimental cardiopulmonary resuscitation. J Am Coll Cardiol. 1994;24:804-812.
27. Peatfield RC, Sillett RW, Taylor D, et al. Survival after cardiac arrest in the hospital. Lancet. 1977;1:1223-1225.
28. Bedell SE, Delbanco TL, Cook EF, et al. Survival after cardiopulmonary resuscitation in the hospital. N Engl J Med. 1983;309:569-576.
29. Landzberg JS, Parker JD, Gauthier DF, et al. Effects of myocardial al-adrenergic receptor stimulation and blockade on contractility in humans. Circulation. 1991;84:1608-1614.
30. Duncker DJ, Zhang J, Crampton MJ, et al. Alpha 1-adrenergic tone does not influence the transmural distribution of myocardial blood flow during exercise in dogs with pressure overload left ventricular hypertrophy. Basic Res Cardiol. 1995;90:73-83.
31. Lefkowitz RJ. Neurotransmission: the autonomic and somatic motor nervous system. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's, The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill; 1996:125.
32. Gregorini L, Marco J, Kozakova M, et al. α-Adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation. 1999;99:482-490.
33. 2-adrenergic agonist for cardiopulmonary resuscitation. J Am Coll Cardiol. 2001;37:951-956.
34. 2-adrenergic agonist for cardiac resuscitation. J Lab Clin Med. 2002;140:27-34.
35. Fox AW. Vascular vasopressin receptors. Gen Pharmacol. 1988;19:639-647.
36. Coudrey L. The troponins. Arch Intern Med. 1998;158:1173-1180.